Could CAR-T Cell Therapy One Day Play a Role in Cold Agglutinin Disease?

CAR-T cell therapy has become one of the most revolutionary developments in modern medicine. Originally designed as an advanced treatment for certain blood cancers, researchers are now exploring whether this highly personalized immune therapy may eventually have applications in severe autoimmune diseases as well—including diseases involving abnormal B-cell activity.

Because Cold Agglutinin Disease (CAD) is both an autoimmune hemolytic anemia and a clonal B-cell disorder, some patients naturally wonder whether CAR-T therapy could someday become relevant in CAD treatment. While CAR-T is not currently an approved treatment for CAD, understanding why it is being discussed in autoimmune research may help patients appreciate where future therapies may be headed.

What Is CAR-T Cell Therapy?

CAR-T stands for Chimeric Antigen Receptor T-cell therapy.

In simple terms, doctors collect a patient’s own T-cells (immune cells), genetically modify them in a laboratory so they can recognize a specific target, then infuse them back into the patient. These engineered T-cells can then seek out and destroy cells carrying that target.

This treatment has produced remarkable results in certain cancers, particularly:

B-cell leukemias
B-cell lymphomas
Multiple myeloma

Why Might CAR-T Matter to Cold Agglutinin Disease?

Cold Agglutinin Disease is not simply “anemia caused by antibodies.” Modern research has shown that primary CAD is typically associated with an underlying clonal B-cell lymphoproliferative disorder in the bone marrow. In other words, CAD is often driven by an abnormal population of B-cells producing the pathogenic cold agglutinin antibody.

That is important because CAR-T therapy was originally developed to target abnormal B-cells in blood cancers.

Researchers therefore recognize a conceptual overlap:

Lymphoma/Leukemia: Abnormal B-cells become malignant
CAD: Abnormal B-cells produce harmful autoantibodies

Though the disease processes are different, both involve problematic B-cell populations.

Is CAR-T Being Used for Autoimmune Disease?

Yes—but only experimentally at this time. (2026)

In recent years, researchers have begun studying CAR-T therapy in severe refractory autoimmune diseases, particularly diseases believed to be strongly B-cell mediated. Early reports have shown promising results in selected patients with:

Systemic lupus erythematosus (SLE)
Systemic sclerosis / scleroderma
Inflammatory myositis
Myasthenia gravis
Other severe autoimmune hematologic disorders

Has CAR-T Been Studied Specifically in CAD?

At present, there are no established clinical CAR-T protocols specifically for Cold Agglutinin Disease.

However, because CAD is increasingly understood as a B-cell–driven clonal disorder, it is possible that future cellular therapies could eventually be explored in highly refractory cases.

Whether CAR-T itself—or a modified next-generation cell therapy—will become relevant remains unknown.

Why CAR-T Is Not a Near-Term CAD Treatment

Despite the excitement, CAR-T remains an intensive therapy with substantial limitations:

Risk of severe immune reactions (cytokine release syndrome)
Neurologic complications in some patients
Temporary or prolonged immune suppression
Need for specialized treatment centers
Very high cost

Because current CAD therapies are often less intensive, CAR-T would likely only ever be considered in highly selected refractory cases unless future versions become much safer and easier to administer.

Current Standard CAD Treatments Remain Very Different

Today, CAD treatment generally focuses on:

Complement inhibition (such as Enjaymo / sutimlimab)
B-cell depletion with rituximab-based therapy
Combination chemoimmunotherapy in selected severe cases
Supportive care / transfusion management

Leading Experts and Institutions Involved in CAD and Related Research

Dr. Sigbjørn Berentsen – Haugesund Hospital, Norway
Dr. Patrick Swiecicki – Mayo Clinic
Dr. Wilma Barcellini – University of Milan
Mayo Clinic – Major U.S. referral center for CAD and autoimmune hematology
University Hospital Erlangen (Germany) – Active in autoimmune CAR-T research
University of Pennsylvania / Penn Medicine – Major CAR-T development center

The Bottom Line

CAR-T therapy is currently a transformative treatment for certain leukemias, lymphomas, and other blood cancers. It is now being actively explored as a possible treatment for severe autoimmune diseases due to its ability to target and potentially reset problematic B-cell populations.

Because Cold Agglutinin Disease is a B-cell–driven autoimmune hemolytic anemia with underlying clonal lymphoproliferative features, it is scientifically reasonable that CAD patients may hear discussion of CAR-T in future research conversations.

However:

CAR-T is not currently a standard or approved treatment for CAD
Its role in CAD remains theoretical and investigational
Any future use would depend on major advances in safety, cost, and clinical evidence

Still, the expanding exploration of CAR-T and related cellular therapies reflects a broader trend in medicine: moving beyond symptom control and toward therapies that may one day fundamentally reset or correct immune dysfunction at its source.

Best Approach if a Person With Cold Agglutinin Disease Wants to Pursue Experimental or Worldwide Programs

If someone with Cold Agglutinin Disease (CAD), especially someone with multiple autoimmune problems, wants to explore research studies, investigational treatment programs, or advanced referral centers, the best approach is usually to think in terms of organized eligibility rather than simply “finding a trial.” CAD is a rare disease, and many programs will only review a case seriously if the diagnosis, severity, prior treatments, and related autoimmune conditions are clearly documented. ClinicalTrials.gov is the main public database for studies in the United States and many international sites, and the European Medicines Agency’s CTIS website is the official public search portal for trials in the EU/EEA. NIH and NORD both direct patients to those tools when looking for studies. [oai_citation:0‡ClinicalTrials.gov](https://clinicaltrials.gov/?utm_source=chatgpt.com)

The first step is to assemble a clean medical summary packet. That packet should usually include: confirmed CAD diagnosis; whether the case is primary CAD versus secondary cold agglutinin syndrome; hemoglobin trend; bilirubin, LDH, haptoglobin, reticulocyte count, DAT/C3 results; cold agglutinin titer and thermal amplitude if available; bone marrow findings; monoclonal protein studies; infection history; thrombosis history; transfusion history; prior use of rituximab, bendamustine, sutimlimab/Enjaymo, steroids, IVIG, or other immunologic therapies; and a list of all confirmed autoimmune diagnoses. This matters because modern reviews describe CAD as not only an autoimmune hemolytic anemia but also a specific clonal B-cell bone marrow disorder, which affects how research centers think about eligibility and treatment strategy. [oai_citation:1‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12891375/?utm_source=chatgpt.com)

The second step is to get reviewed by a hematologist at a center that sees autoimmune hemolytic anemia and rare blood disorders regularly. Mayo Clinic publicly identifies hematologists with Cold Agglutinin Disease among their focus areas, including Dr. Richard L. Godby in Rochester, and Mayo notes that its blood disorder specialists conduct clinical trials and national studies. NORD also maintains Rare Disease Centers of Excellence and patient-facing resources for finding experts and clinical trials. [oai_citation:2‡Mayo Clinic](https://www.mayoclinic.org/biographies/godby-richard-l-m-d/bio-20577359?utm_source=chatgpt.com)

The third step is to search broadly in three lanes:

CAD-specific trials — studies enrolling primary CAD or cold autoimmune hemolytic anemia patients.
Autoimmune cytopenia trials — some trials group CAD with broader autoimmune blood disorders rather than listing it alone.
Autoimmune cell therapy programs — relevant mainly if the person also has another severe autoimmune diagnosis that is already being studied in a CAR-T or cellular therapy program.

That distinction matters. At the moment, CAD-specific CAR-T treatment is not an established clinical pathway. However, autoimmune CAR-T research is real and expanding, especially in diseases such as lupus, systemic sclerosis, and myositis. University Hospital Erlangen publicly states that it has used CAR-T in autoimmune disease and currently asks that inquiries to its CAR-T autoimmune program be limited to myositis, systemic lupus erythematosus, and systemic sclerosis. So for a CAD patient with overlapping autoimmune disease, the “door” may be through the other autoimmune diagnosis rather than CAD itself. [oai_citation:3‡DZI Erlangen](https://www.dzi.uk-erlangen.de/en/immunotherapy/?utm_source=chatgpt.com)

The fourth step is to contact programs with a short, structured inquiry rather than a long personal history. The most effective first message usually includes:

age and country/state
confirmed diagnosis or diagnoses
whether CAD is primary or secondary
current disease burden and main symptoms
major prior treatments and response
whether transfusions or hospitalizations have been needed
whether bone marrow biopsy or monoclonal B-cell findings are present
whether the person can travel for screening

This makes it easier for a trial coordinator or referral office to decide quickly whether the case should be reviewed.

The fifth step is to understand that eligibility often turns on details patients do not expect. Trial programs may exclude someone because of active infection, recent rituximab timing, low blood counts outside the study window, unstable heart/lung disease, poor kidney/liver function, prior malignancy rules, or because the patient’s autoimmune overlap makes the diagnosis “too complex” for a narrow protocol. NIH notes that trial listings include who may participate, locations, and contact information, and that the information should be used together with a health professional’s advice. [oai_citation:4‡National Institutes of Health (NIH)](https://www.nih.gov/health-information/nih-clinical-research-trials-you/finding-clinical-trial?utm_source=chatgpt.com)

A practical worldwide strategy is:

start with the treating hematologist and ask for a one-page referral summary
search ClinicalTrials.gov for “cold agglutinin disease,” “autoimmune hemolytic anemia,” “autoimmune cytopenia,” and any other confirmed autoimmune diagnosis
search the EU/EEA CTIS portal for the same terms
use NORD resources to identify rare-disease centers and trial information
contact one or two high-volume academic centers rather than sending requests everywhere at once
keep a single updated PDF packet ready for coordinators and referral offices

In other words, the best approach is usually not “find the most exotic program in the world,” but rather “make the case easy for the right program to assess.” For a CAD patient with multiple autoimmune issues, the most realistic path may be through a major hematology center, a rare-disease referral program, or an autoimmune trial tied to one of the overlapping diagnoses rather than CAD alone. [oai_citation:5‡ClinicalTrials.gov](https://clinicaltrials.gov/?utm_source=chatgpt.com)